The latest price target for Medpace Holdings (NASDAQ:MEDP) was reported by Barclays on March 6, 2026. The analyst firm set a price target for $500.00 expecting MEDP to rise to within 12 months (a possible 10.22% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for Medpace Holdings (NASDAQ:MEDP) was provided by Barclays, and Medpace Holdings upgraded their equal-weight rating.

The last upgrade for Medpace Holdings Inc happened on March 6, 2026 when Barclays raised their price target to $500. Barclays previously had an underweight for Medpace Holdings Inc.

The last downgrade for Medpace Holdings Inc happened on October 2, 2025 when Barclays changed their price target from $450 to $425 for Medpace Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Medpace Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Medpace Holdings was filed on March 6, 2026 so you should expect the next rating to be made available sometime around March 6, 2027.

While ratings are subjective and will change, the latest Medpace Holdings (MEDP) rating was a upgraded with a price target of $500.00 to $500.00. The current price Medpace Holdings (MEDP) is trading at is $453.64, which is out of the analyst’s predicted range.